We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

This study is currently recruiting participants.
Verified July 2017 by John Koreth, MD, Dana-Farber Cancer Institute
Sponsor:
ClinicalTrials.gov Identifier:
NCT01937468
First Posted: September 9, 2013
Last Update Posted: July 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
Miltenyi Biotec GmbH
Prometheus Laboratories
National Cancer Institute (NCI)
Information provided by (Responsible Party):
John Koreth, MD, Dana-Farber Cancer Institute
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: November 2020
  Estimated Primary Completion Date: November 2018 (Final data collection date for primary outcome measure)